Report an error

Spotted something inaccurate in “Dual PD-1/VEGF Bispecific Antibody Extends Survival Over Standard Immunotherapy in Lung Cancer”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.